A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 daysCharlotte Benson, Chris Twelves|British Journal of Cancer|2006Cited by 257